Clinical Trial Update: OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease [Phase 2]

View source ↗

Summary

This update notes that the Phase II randomized, controlled trial of OGT 918 for Gaucher disease (neuronopathic form) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• OGT 918

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Gaucher Disease | Phase 2 | Status: COMPLETED